NASDAQ:AMRS - Amyris Stock Price, Forecast & News

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris shares reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris Inc (NASDAQ:AMRS) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.53) by $0.02. The biotechnology company had revenue of $34.95 million for the quarter, compared to analysts' expectations of $21.60 million. View Amyris' Earnings History.

Amyris is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Amyris.

Amyris issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$150 million, compared to the consensus revenue estimate of $$148.65 million.

2 brokers have issued 12-month price objectives for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 178.6% from the stock's current price. View Analyst Price Targets for Amyris.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

Media stories about AMRS stock have trended very positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amyris earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Amyris.

Amyris saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 19,160,000 shares, an increase of 11.5% from the January 15th total of 17,190,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the short-interest ratio is presently 16.2 days. Currently, 38.5% of the company's stock are short sold. View Amyris' Current Options Chain.

Some companies that are related to Amyris include Phillips 66 (PSX), Marathon Petroleum (MPC), Valero Energy (VLO), HollyFrontier (HFC), CVR Energy (CVI), PBF Energy (PBF), World Fuel Services (INT), Delek US (DK), Renewable Energy Group (REGI), Clean Energy Fuels (CLNE), REX American Resources (REX), Green Plains (GPRE), Adams Resources & Energy (AE) and Gevo (GEVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Canopy Growth (CGC), Advanced Micro Devices (AMD), Intel (INTC), MEI Pharma (MEIP), General Electric (GE) and Amarin (AMRN).

Amyris' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (8.01%), Pinnacle Associates Ltd. (1.29%), State Street Corp (0.83%), Essex Investment Management Co. LLC (0.42%), Goldman Sachs Group Inc. (0.29%) and Rice Hall James & Associates LLC (0.18%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.

AMRS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Goldman Sachs Group Inc., Principal Financial Group Inc., Alliancebernstein L.P., Bank of America Corp DE and Rice Hall James & Associates LLC. View Insider Buying and Selling for Amyris.

AMRS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Pinnacle Associates Ltd., Essex Investment Management Co. LLC, State Street Corp, Spark Investment Management LLC, Virtus ETF Advisers LLC, Levin Capital Strategies L.P. and UBS Group AG. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Insider Buying and Selling for Amyris.

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $3.41.

Amyris has a market capitalization of $359.76 million and generates $80.42 million in revenue each year. The biotechnology company earns $-230,240,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. Amyris employs 414 workers across the globe.View Additional Information About Amyris.

The official website for Amyris is http://amyris.com/.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]